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AIM:  
 The aim of this study is to compare the effect of Dexmedetomidine and 
Lidocaine in preventing cough during emergence from general anaesthesia for 
thyroidectomy.  
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OBJECTIVES: 
1.Primary Objective:  
The primary objective is to compare the effect of Dexmedetomidine and Lidocaine in 
preventing cough during emergence from general anaesthesia for thyroidectomy. 
2.Secondary Objectives:  
The secondary objectives are: 
a) To compare the effect of Dexmedetomidine and Lidocaine in attenuating haemodynamic 
responses during emergence from general anaesthesia for thyroidectomy.  
b) To compare the effect of Dexmedetomidine and Lidocaine on time taken to awaken from 
general anaesthesia for thyroidectomy.  
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INTRODUCTION: 
 
Postoperative neck haematoma requiring emergent surgical evacuation is a rare but 
dreaded complication of thyroidectomy as the mortality rate is high. Bleeding frequently 
occurs in the case of sudden violent cough, sneeze or vomit, especially during extubation. So, 
it is reasonable to take measures to prevent cough during emergence from general 
anaesthesia, so as to prevent the possible life threatening complication of post thyroidectomy 
neck haematoma causing airway compromise and possibly, death. Dexmedetomidine has 
been successfully used to attenuate the haemodynamic responses to tracheal intubation and 
extubation, in doses ranging between 0.5 mcg/kg to 1 mcg/kg. Lidocaine has also been used 
in doses between 1 mg/kg to 2 mg/kg to prevent cough during emergence from general 
anaesthesia. Studies are not available till date comparing these drugs in preventing cough in 
thyroidectomy. The purpose of this study is to compare the effect of Dexmedetomidine and 
Lidocaine in preventing cough during emergence from general anaesthesia for thyroidectomy 
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LITERATURE REVIEW: 
 
General Anaesthesia:  
 General anaesthesia (1) can be broadly defined as a state of reversible 
depression of the central nervous system induced by drugs resulting in the loss of 
response to and perception of any external stimuli. The components of such an 
anaesthetic state include amnesia, unconsciousness, immobility, analgesia and 
attenuation of autonomic responses to any noxious stimulation.  
In deep plane of anaesthesia, the patency of airway can be compromised. 
Securing and maintaining the patency of the airway is essential in such a state of 
anaesthesia. Endotracheal tube, supra-glottic airway device can be used to secure 
airway and maintain ventilation. Endotracheal intubation was described first as early 
as in 1788 as a means of resuscitation of the collapsed patient (“apparent dead”), but it 
was not used for the delivery of anaesthesia until almost for the next 100 years. 
Placement of endotracheal tube not only secures the airway but also allows delivery of 
anaesthetic gases for maintenance of anaesthesia throughout the surgery.  
 Cough:  
Cough is a very important protective reflex that occurs via the stimulation of a 
composite reflex arc. It increases clearance of secretions and particulate matter from 
the airways and protects the airway from aspiration of foreign body occurring as a 
result of aspiration or inhalation of particulate substance, pathogens, secretions, 
postnasal drip, inflammation, and mediators associated with inflammation. 
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 Under normal circumstances coughing serves an important defensive role in 
the airways and lungs. (2). The cough reflex is initiated by the irritation of cough 
receptors which are found in the trachea, main carina, branching points of large 
airways, and more distal smaller airways, also the pharynx. Tracheal, bronchial and 
laryngeal receptors respond to both chemical and mechanical stimuli. Chemical 
receptors which are sensitive to heat, acid, and capsaicin-like compounds trigger the 
cough reflex via activation of the type 1 vanilloid (capsaicin) receptor. Additionally, 
more such airway receptors are located in the eardrums, external auditory canal, 
pharynx, paranasal sinuses, pleura, diaphragm, stomach and pericardium. These are 
likely to be mechanical receptors only, which can be stimulated by triggers such as 
displacement or touch. (3) (4). 
Impulses from stimulated cough receptors traverse an afferent pathway via the 
vagus nerve to the cough centre in the medulla oblongata, which itself may be under 
some control by higher cortical centres. The cough centre generates an efferent signal 
that travels down the vagus, phrenic, and spinal motor nerves to expiratory 
musculature to produce the cough. 
The cough reflex arc is constituted by: (2) 
1. Afferent pathway: Sensory nerve fibres which are branches of the vagus nerve, 
located in the ciliated epithelium of the upper airways (auricular, pulmonary, superior 
laryngeal, pharyngeal, gastric) and oesophageal, and cardiac branches from the 
diaphragm. The afferent impulses go to medulla oblongata diffusely. 
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2. Central Pathway (cough centre): a central co-ordinating region for cough is 
present in the upper brain stem and the pons. 
3. Efferent pathway: Impulses from the cough centre travel via the vagus, phrenic, 
and spinal motor nerves to diaphragm, abdominal wall and muscles. The nucleus 
retro-ambigualis, by phrenic and other spinal motor nerves, sends impulses to the 
expiratory and inspiratory muscles; and the nucleus ambiguus, by the laryngeal 
branches of the vagus to the larynx.  
The observation that women are more likely to develop chronic cough than 
men explains the sex-related differences in cough reflex sensitivity. (5) (6).  
The mechanical events of cough can be categorised into three phases (7) : 
1. Inspiratory phase: Inhalation, which generates the volume required for an effective 
cough. 
2. Compression phase: Closure of the larynx combined with contraction of diaphragm, 
muscles of abdominal wall, and chest wall result in a swift rise in intra-thoracic 
pressure. 
3. Expiratory phase: The glottis opens, which results in high expiratory airflow and 
the coughing sound. Compression of large airway occurs. Mucus from the airways is 
dislodged by the high flows, which also allows removal of mucus from the trachea-
bronchial tree.   
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During vigorous coughing, intra-thoracic pressures can reach up to 300 mm Hg 
and expiratory velocities may reach up to 800 kilometre per hour. (8). These velocities 
and pressures are responsible for the beneficial effects of cough on mucus clearance.  
Also, they are responsible for numerous other complications of cough, 
including self-consciousness, exhaustion, headache, insomnia, hoarseness, 
musculoskeletal pain, dizziness, urinary incontinence and excessive perspiration. (9). 
Stimulation of the larynx produces a choking type of cough which is not preceded by 
inspiration. Inadequate muco-ciliary clearance mechanisms (as in cystic fibrosis or 
bronchiectasis) may produce a pattern of coughing with less violent acceleration of air 
and a sequence of interrupted expirations without any intervening inspiration. (2).  
Cough in Tracheal Extubation: 
 Tracheal extubation can be performed while either patients are under deep 
anaesthesia or when they are awake. Each technique has its own pros and cons. (10) 
(11). Extubation in a light plane of anaesthesia is the most important concern in awake 
extubation. While extubation in deep plane of anaesthesia may leave the patient with 
an unprotected airway. Deep extubation might prevent the problem of cough and 
straining, (10) as opposed to awake extubation, and avoid the possibilities of 
laryngospasm and oxygen desaturation. (10) (11). Nonetheless, deep extubation 
technique has the potential of exposing the patients to the risk of airway obstruction or 
aspiration as it prolongs the time interval between tracheal extubation and return of 
protective airway reflexes, which is always a great concern after general anaesthesia. 
Wakefulness is determined by the return of pharyngeal or laryngeal reflexes, eye 
17 
 
opening, grimacing, coughing, and purposeful movement, and in this situation, the 
patients are in full control of their airway reflexes and can maintain adequate 
ventilation. (10) (11). 
Events such as aspiration, laryngospasm, inadequate ventilatory drive or airway 
obstruction can result in hypoxaemia. Such hypoxaemia can usually be corrected 
immediately. Occasionally, post-extubation hypoxaemia can progress quickly, and if 
uncorrected, can result in very serious complications like brain damage and death. 
(12). 
 Coughing is a common clinical problem in most patients during emergence 
from general anaesthesia in the presence of a tracheal tube. (13). Apart from 
respiratory and airway related events, emergence from general anaesthesia can result 
in a number of undesirable side effects including hypertension, tachycardia and 
agitation. These side effects may cause haemorrhage from the surgical wound site and 
also increase the in intraocular and intracranial pressures. (14). 
Administration of opioids or local anaesthetics, and extubation in a deeper 
plane of anaesthesia have been suggested to prevent such adverse emergence events. 
(11) (15) (16). The administration of opioids before emergence may be beneficial for 
preventing agitation, cough and haemodynamic response but, it may cause 
unpredictable and undesirable delayed emergence. (16). 
 In paranasal sinus and nasal operations, smooth emergence from general 
anaesthesia is desirable because bucking and coughing during awakening very often 
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stimulate the oozing of blood, which may further lead to more airway stimulation and 
subsequently to more coughing and bucking. (10).  
The incidence of coughing during emergence from general anaesthesia in the 
presence of endotracheal tube has been estimated as ranging between 38 and 96%. 
(17) (18). Bucking and coughing induced by endotracheal tube can complicate 
emergence from general anaesthesia. They may possibly be associated with breath-
holding which may cause a decrease in oxygen saturation and hypoxaemia (19).  
Moreover, bucking and coughing can precipitate serious bronchospasm in patients 
with hyper-reactive airways. (20) (21). They can also precipitate larngospasm post 
extubation, which can further lead to severe hypoxaemia, brain damage and death.  
The tracheal tube and its cuff stimulate the stretch receptors and the rapidly 
acting irritant receptors in the trachea. (22). Those irritant receptors are thought to be 
the receptors involved in the cough reflex. (23) (24). Any stimulation such as head 
turning, oropharyngeal suctioning, pillow removal, and bodily movements can cause 
tracheal irritation and awakening.  
Thyroidectomy: 
 Thyroidectomy is the procedure of surgical removal of whole or part of the 
thyroid gland. It is done to treat diseases of the thyroid gland including: 
 Large goitres or thyroid nodules causing symptomatic obstruction 
 Hyperthyroidism 
 Thyroid cancer 
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 Multi-nodular Goitre 
Thyroid surgery (25) was performed well before the physiology of thyroid gland was 
understood.  The procedures were often fraught with complications, including 
infection, massive haemorrhage and injury to adjacent structures in the neck, all of 
which were associated with morbidity and mortality rates of as high as 40%. With the 
advent of aseptic technique and improvement in technology, mortalities and 
morbidities associated with these surgeries decreased.  
Post-Thyroidectomy Neck Haematoma:  
Nowadays, thyroidectomy, compared to olden days, is a relatively safe surgical 
procedure for treating several diseases of the thyroid gland compared with conser-
vative methods. The common indications for thyroidectomy are the presence of 
thyroid nodules, multinodular goitres and thyroid carcinoma. The thyroid gland is an 
organ with high blood flow and is second only to the adrenal glands in terms of 
relative vascular perfused organ in the body (26). Post-operative bleeding, therefore, 
may be a complication of thyroid surgery. The reported incidence of post-
thyroidectomy bleeding varies between approximately 0.05 and 1.25 percent, but 
depending on patient and surgeon factors (like experience of the surgeon, number of 
thyroidectomy done), it can be up to 4 percent. (27) (28). The incidence of post 
thyroidectomy bleeding is 1.36% in most centres, of which re-exploration was 
required in about 0.3%. (29). Shelby H et al (29) reported that, during a 40-year period 
during which 10,201 thyroidectomies were performed at the Royal North Shore 
Hospital, 1.2% required re-operation for haemorrhage.  
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Generally, the risk of post thyroidectomy bleeding mainly depends on the 
extent of the operation, patient factors (such as size of tumour, male gender, older age) 
and the experience of the operating surgeons (28) (27). Although rare, the post-
thyroidectomy bleeding may be life-threatening. Although some hematomas present 
superficially, in severe cases, cervical hematomas can compress the airway, 
necessitating surgical evacuation or tracheostomy in about 4.8% of patients. (30) (31) 
(32) (33). Death has occurred from cardiac arrest and respiratory distress. (34) (35). 
Occasionally, the haemorrhage also necessitates blood transfusions, 7.1%. (30) (31) 
(27). Mortality is about three times more likely in patients who had hematoma. 
Postoperative haemorrhage has been attributed to three categories of risk: surgical 
technique, patient predisposition, and thyroid pathology. (36). Smokers have a 
recognized increased bleeding tendency. (38) (36). Most bleeding after thyroidectomy 
is due to higher systolic blood pressures in the immediate post-operative period. (38). 
Higher systolic blood pressures postoperatively in excess of 150 mmHg has been 
associated with an increased risk of haemorrhage after thyroid surgery. (37). Graves’ 
disease and hyperthyroidism were found to be independent risk factors for post-
thyroidectomy bleeding. (37). Neck lymph node dissection is an independent predictor 
for post-thyroidectomy bleeding. (37). Patients who need neck dissection had 
malignant pathological diagnosis and underwent a large thyroid tissue removal, led to 
a larger dead space and allowed a hematoma to form easily. Neck dissection requiring 
greater extent of dissection is more likely to damage the surrounding tissue, such as 
infra-hyoid muscles or jugular vein. Bleeding frequently occurred after sudden violent 
cough, sneeze or vomiting often during immediate post-operative period.(37). Violent 
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cough or vomit and unexpected hypertension were also responsible for the 
subcutaneous tissue bleeding. (37). On sudden violent cough, sneeze or vomit, the 
upper pole would lift with thyroid cartilage, generating forces between the upper pole 
and cricothyroid, making the part cricothyroid evulsion, loosing bleeding ligation, and 
lead to the bleeding after operation. (37).  
Methods to Prevent Cough during Extubation:  
Several strategies have been tried to minimise or prevent cough during 
emergence from general anaesthesia in the presence of tracheal tube. The strategy can 
be the extubation technique or a pharmacological intervention to prevent coughing 
during emergence from general anaesthesia.  
Extubation in deep plane of anaesthesia has been advocated to obtund the 
laryngeal reflexes. (39) . This technique offers the advantage of a smooth extubation 
with minimal airway stimulation, thereby preventing cardiovascular stimulation and 
subsequent haemodynamic response, reducing coughing, and reducing intracranial, 
intraocular, and middle ear pressure changes. Removal of the tracheal tube while 
patients remain deeply anesthetised may be advantageous in various situations (10). 
Intravenous lidocaine is widely used to prevent haemodynamic and airway 
reflexes during extubation but the duration of action is short. (40). Lidocaine 
alkalinised with 8.4% sodium bicarbonate has been used to prevent cough during 
emergence from general anaesthesia. (41). Alkalinised Lidocaine instilled through the 
endotracheal tube suppressed cough if given approximately 5 min before extubation, 
and found it to be superior to intravenous injection given 3 min before extubation. 
(42).  
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Low dose remifentanil has been used to conduct a smooth extubation. (43). 
Alfentanil has also been used to suppress cough and agitation during emergence from 
general anaesthesia. (16). The administration of opioids before emergence may be 
beneficial for preventing cough, agitation, and hemodynamic response but, it may 
cause unpredictable delayed emergence. (16).  
Haemodynamic Responses during Emergence from General Anaesthesia:  
 Emergence from anesthesia and tracheal extubation are usually associated with 
tachycardia, hypertension and high plasma catecholamine levels. (44). These 
responses may lead to post-operative haemorhage, pulmonary oedema, 
cerebrovascular haemorrhage and cardiac failure. (45). Various drug regimens and 
techniques have been used from time to time for attenuating the stress response to 
laryngoscopy and intubation, including opioids, barbiturates, benzodiazepines, beta 
blockers, calcium channel blockers, dexmedetomidine, lidocaine, vasodilators, or by 
extubation under deep anesthesia. (46) (21) (47) (48) (49) (50) (51) (52) (53).  
Recovery from Anaesthesia:  
 Recovery from anaesthesia may be defined as a state of consciousness of an 
individual when the person is awake or easily aroused and aware of his surroundings 
and identity. (54) (55). Awakening results from elimination of anaesthetic agents from 
the brain. Patients usually respond to verbal stimuli when alveolar anaesthetic 
concentration is decreased to about 30% of minimum alveolar concentration (MAC) 
(MAC awake) if unimpeded by other factors. (55). Recovery from intravenous opioids 
and hypnotics may be more variable and difficult to quantify than recovery from 
inhalational and neuromuscular blocking agents. Patients should not leave the 
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operating room or the post-anaesthesia care unit unless they have a patent airway, 
stable hemodynamic parameters, adequate ventilation and oxygenation. Irrespective of 
age or American Society of Anaesthesiologist physical status category, higher 
incidence of early postoperative respiratory complications is noted when the patient is 
transferred to post anaesthesia care unit in an unresponsive state.  (56). 
The entire process of recovery after anaesthesia can be divided into three 
phases.  
1.Immediate recovery - consists of recovery of protective airway reflexes, 
return of consciousness and resumption of motor activity. This stage usually lasts for a 
short time. 
2. Intermediate recovery - the patient regains his power of coordination and the feeling 
of dizziness disappears. This stage usually lasts for one hour after short anaesthetic. 
Outpatient may be considered fit for discharge with a responsible escort.  
3. Long-term recovery - full recovery of coordination and higher intellectual function. 
It may last for hours or even days. (56) (57). Patients cannot be considered fully 
recovered until they have returned to their preoperative physiological state. (54).  
Abnormally slow pace of regaining consciousness after general anaesthesia is 
characterised by persistent somnolence. It is defined as a state of unresponsiveness 
from which the patient cannot be aroused. In otherwise healthy patients who have 
undergone short operative procedures, delayed recovery is usually secondary to some 
underlying undiagnosed condition or medical error. (54). Even after prolonged 
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anaesthesia, a response to stimulation should occur between 60 and 90 minutes. (54) 
(58). The incidence of unresponsiveness between 15 and 90 min after general 
anaesthesia among mixed surgical patients is about 9%. (30) Dissociative coma, 
thyroid failure, myxoedema coma, hunter syndrome (mucopolysaccharide storage 
disease), drug abuse, valproate toxicity and lidocaine infusion for arrhythmias are 
some rare causes of delayed recovery. (54) (55).  
Risk Factors for Delayed Awakening: 
Table 0.0 (55) 
 
Dexmedetomidine: (1) (58) (59) 
 Dexmedetomidine is a highly selective, specific, and potent alpha adrenergic 
agonist (1,620:1 alpha2 to alpha1). This drug is the dextroisomer and 
pharmacologically active component of medetomidine, which has been used for many 
years in veterinary practice for its hypnotic, sedative, and analgesic effects. Compared 
with clonidine, Dexmedetomidine is seven to ten times more selective for alpha2 
25 
 
receptors and has a shorter duration of action than clonidine. In this regard, 
Dexmedetomidine is considered a full agonist at the alpha2 receptor, whereas 
clonidine is a partial agonist (ratio of alpha2 to alpha1 activity for clonidine is 220:1). 
Atipamezole is a specific and selective alpha2 receptor antagonist that rapidly and 
effectively reverses the sedative and cardiovascular effects of intravenous 
Dexmedetomidine. The elimination half time of Dexmedetomidine is 2 to 3 hours 
compared with 6 to 10 hours for c1onidine. Dexmedetomidine is highly protein bound 
(>90%) and undergoes extensive hepatic metabolism. The resulting methyl and 
glucuronide conjugates are excreted by the kidneys. Dexmedetomidine has weak 
inhibiting effects on cytochrome P450 enzyme systems that might manifest as 
increased plasma concentrations of opioids as administered during anaesthesia. As 
with clonidine, pre-treatment with Dexmedetomidine attenuates hemodynamic 
responses to tracheal intubation, decreases plasma catecholamine concentrations 
during anaesthesia, decreases peri-operative requirements for inhaled anaesthetics and 
opioids, and increases the likelihood of hypotension. Dexmedetomidine decreases 
MAC for volatile anaesthetics in animals by > 90% compared with a plateau effect 
between 25% to 40% for clonidine.  
In patients, isoflurane MAC was decreased 35% and 48% by 
Dexmedetomidine plasma concentrations of 0.3 ng/mL and 0.6 ng/mL, respectively.  
Despite marked dose-dependent analgesia and sedation produced by this drug, there is 
only mild depression of ventilation. Dexmedetomidine in high doses (loading dose of 
1 mcg/kg intravenous followed by 5 to 10 mcg/kg/hour intravenous) produces total 
intravenous anaesthesia without associated depression of ventilation. The preservation 
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of breathing provides a potential anaesthetic technique for patients with a difficult 
upper airway. As with c1onidine, Dexmedetomidine has been reported to be effective 
in attenuating the cardio-stimulatory and post-anaesthetic delirium effects of 
ketamine. Addition of 0.5 mcg/ kg Dexmedetomidine to lidocaine being administered 
to produce intravenous regional anaesthesia improves the quality of anaesthesia and 
postoperative analgesia without causing side effects. Dexmedetomidine increases the 
range of temperatures without triggering thermoregulatory defenses. 
Dexmedetomidine, like clonidine, is likely to promote perioperative hypothermia and 
also prove to be an effective treatment for shivering. Severe bradycardia may follow 
the administration of Dexmedetomidine and cardiac arrest has been reported in a 
patient receiving a Dexmedetomidine infusion as a supplement to general anaesthesia 
Dexmedetomidine (0.2 to 0.7 mcg/ kg/ hour intravenous) is useful for sedation of 
postoperative critical care patients in an intensive care unit environment, particularly 
when mechanical ventilation via a tracheal tube is necessary. In comparison with 
remifentanil, Dexmedetomidine infusions do not result in clinically significant 
depression of ventilation and sedation exhibits some similarity with natural sleep. 
Following tracheal extubation, Dexmedetomidine-sedated patients breathe 
spontaneously and appear calm and relaxed. Both clonidine and Dexmedetomidine are 
useful in the intensive care unit to prevent drug withdrawal symptoms following long-
term sedation with benzodiazepines. Its sympatholytic and vagomimetic actions can 
cause systemic hypotension and bradycardia. The ability to specifically antagonize the 
sedative effects of Dexmedetomidine with atipamezole may be useful.  
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Lidocaine: (1) (58) (59) 
 Lidocaine was synthesized as an amide local anaesthetic by Lofgren in 1943. 
Lidocaine is effective topically and is a highly efficacious cardiac antidysrhythmic 
drug. Lidocaine prevents transmission of nerve impulses (conduction blockade) by 
inhibiting passage of sodium ions through ion-selective sodium channels in nerve 
membranes. In addition to sodium ion channels, local anaesthetics block voltage-
dependent potassium ion channels. Considering the similarity in structure between 
voltage-dependent calcium ion channels and sodium ion channels, it is quite possible 
that calcium ion currents (L-type most sensitive) may also be blocked by local 
anaesthetics. Although all local anaesthetics are considered primarily ion channel 
blockers, there is also considerable evidence that these drugs may also act on G-
protein coupled receptors. Local anaesthetics can be used to produce topical 
anaesthesia by placement on the mucous membranes of the nose, mouth, 
tracheobronchial tree, oesophagus, or genitourinary tract. Lidocaine 2% to 4% is most 
often used.  The inhalation of local anaesthetics by normal subjects does not alter 
airway resistance and may even produce mild bronchodilation. In contrast, inhalation 
of nebulized lidocaine can cause bronchoconstriction in some patients with asthma, 
which may become an important consideration when bronchoscopy is planned in these 
patients. The intravenous injection of a local anaesthetic solution into an extremity 
isolated from the rest of the systemic circulation by a tourniquet produces a rapid 
onset of anaesthesia and skeletal muscle relaxation. The duration of anaesthesia is not 
dependent on the specific local anaesthetic, and it is determined by how long the 
tourniquet is kept inflated. The mechanism of action by which local anaesthetics 
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produce intravenous regional anaesthesia is not clearly known, but it probably reflects 
the action of the local anaesthetic on nerve endings as well as nerve trunks. 
 Lidocaine is the most frequently selected amide local anaesthetic for 
producing this type of regional anaesthesia. Apart from suppressing ventricular 
cardiac dysrhythmias, the intravenous administration of lidocaine may also increase 
the defibrillation threshold.  
The principal metabolic pathway of lidocaine is oxidative dealkylation in the 
liver to monoethylglycinexylidide followed by hydro lysis of this metabolite to 
xylidide. Monoethylglycinexylidide has approximately 80% of the activity of 
lidocaine for protecting against cardiac dysrhythmias in animal models. The 
elimination half-time of this metabolite is long, which account for its efficacy in 
controlling cardiac dysrhythmias after the infusion of lidocaine is discontinued. 
Xylidide exhibits only about 10% of the cardiac anti-dysrhythmic activity of 
lidocaine. In humans, approximately 75% of xylidide is excreted in the urine as 4-
hydroxy-2,6-dimethylaniline. Decreased in hepatic blood flow which may occur under 
anaesthesia and hepatic diseases, can decrease the rate of metabolism of lidocaine. For 
instance, compared with normal patients, the elimination half-time of lidocaine is 
increased more than fivefold in patients with liver dysfunction. When patients are 
anesthetised with volatile anaesthetics, decreased hepatic metabolism of lidocaine 
should be anticipated, as hepatic blood flow can be decreased. In the presence of 
pregnancy induced hypertension, maternal clearance of lidocaine is prolonged due to 
decreased hepatic blood flow or HELLP syndrome where there can be hepatic 
necrosis and subsequent impaired hepatic function. Hence, repeated administration of 
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lidocaine can result in higher plasma concentrations than in normotensive pregnant 
women.  
The principal side effects related to the use of lidocaine are allergic reactions 
and systemic toxicity due to excessive plasma and tissue concentrations. Systemic 
toxicity is estimated to result in seizures in 1 to 4 per 1,000 patient exposures.  
Lidocaine has also been observed to suppress cough reflex when used as 
supplement of general anaesthesia. Although the mechanism by which intravenous 
lidocaine suppresses respiratory and laryngeal reflex responses is largely unknown, 
possible effects may include general anaesthesia, depression of motor function and 
direct blockade of noxious stimuli (60). Lidocaine may cause suppression of cough by 
causing depression of brain stem functions. Lidocaine may also act by anaesthetising 
cough receptors in the hypopharynx and trachea. (61). Administration of intravenous 
lidocaine may suppress chemically and mechanically induced airway reflexes, 
including cough reflex. (61).  
Justification for the Study:  
Qing Fan et al (43) studied Dexmedetomidine and Remifentanil in preventing 
cough during extubation in patients undergoing ear surgeries. This study included 75 
patients (25 patients in each arm) in the age group between 20 and 60 years 
undergoing elective middle ear surgery. The patients were randomised into three arms. 
Patients in one arm received Remifentanil 0.03 mcg/kg/minute infusion over 10 
minutes, patients in the second arm received Dexmedetomidine 0.5 mcg/kg infusion 
over 10 minutes and patients in the third arm received Dexmedetomidine 0.7 mcg/kg 
infusion over 10 minutes. Smooth extubation without cough was achieved in 22/25 
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(88%) patients in Remifentanil arm, 15/25 (62.5%) patients in 0.5 mcg/kg 
Dexmedetomidine arm, 22/25 (88%) patients in 0.7 mcg/kg Dexmedetomidine arm. 
There was also less incidence of post-operative nausea and vomiting in both the 
Dexmedetomidine arms. There was no significant difference in time taken for 
awakening between all three arms. This study concluded that both Remifentanil and 
Dexmedetomidine at 0.7 mcg/kg are effective in preventing cough during extubation. 
So, Dexmedetomidine produced a dose-dependent effect in providing smooth 
extubation without significantly prolonging the recovery from anaesthesia. Compared 
to remifentanil, the benefits of dexmedetomidine included hemodynamic stability, 
opioid sparing, and less post-operative nausea and vomiting. The disadvantages of 
dexmedetomidine included lower tidal volume and blood pressure. 
Intravenous Lidocaine was found to suppress the cough reflex produced by 
moving the endotracheal tube. (62). A test dose of 2% lidocaine, 40 mg, followed by 
an additional 150-200 mg injected in less than 60 seconds suppressed the cough reflex 
successfully for 8-9 min during bronchography after tracheal intubation. (63).  
Yukioka H et al (64) studied different doses of Lidocaine in suppressing cough 
during extubation in patients in the age group between 15 and 55 years, undergoing 
orthopaedic, urologic, gynaecologic and general surgeries. One hundred patients were 
randomised in to five arms, with doses of 0.5, 1.0, 1.5 and 2.0 mg/kg Lidocaine and 
placebo (normal saline). The incidence of coughing was 70% in the placebo arm, 65% 
with 0.5 mg/kg Lidocaine, 30% with 1.0 mg/kg Lidocaine, 20% with 1.5 mg/kg 
Lidocaine and 0% with 2.0 mg/kg Lidocaine. The incidence of coughing decreased as 
the dose of intravenous lidocaine increased.  It concluded that the optimal dose of 
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Lidocaine to suppress cough during extubation is 2 mg/kg with no serious adverse 
effects. There was no significant difference in side effects between the different dose 
arms of Lidocaine. Lidocaine has been used in doses between 1 mg/kg to 2 mg/kg as 
intravenous bolus to prevent cough during emergence from general anaesthesia with 
variable results. (64) (65).  
Ashraf MA Moustafa et al (53) compared the efficacy of the 
Dexmedetomidine-Lidocaine combination with each drug alone in suppressing the 
hemodynamic and catecholamine stress responses during tracheal extubation and 
emergence from general anesthesia. in elective orthopaedic surgeries. Sixty 
hypertensive patients (ASA II–III), defined as systolic blood pressure more than 160 
mm Hg and/or diastolic blood pressure more than 95 mmHg, undergoing elective 
orthopaedic surgery were assigned to a randomized in to three arms, with double-blind 
approach. One arm received Dexmedetomidine 0.1 mcg/kg, the second arm received 
Lidocaine 1 mg/kg, and the third arm received Dexmedetomidine and Lidocaine 
combination with same dose with 20 patients in each arm. Incidence of cough was 
secondary outcome in this study. Smooth extubation without cough or with minimal 
cough was achieved in 15/20 (75%) patients in Lidocaine arm, 6/20 (30%) patients in 
Dexmedetomidine arm, 15/20 (75%) patients in combination arm. It was found that 
HR and MAP increased temporarily after tracheal extubation in patients receiving 
Lidocaine. However, these hemodynamic changes were completely inhibited in those 
receiving Dexmedetomidine plus Lidocaine, but suppressed to some extent with 
Dexmedetomidine alone. It concluded that Lidocaine was better in preventing cough 
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during extubation, and Dexmedetomidine was better in suppressing haemodynamic 
responses during extubation.  
The effect of lidocaine on the hemodynamic changes may be because of its 
direct cardiac depression and peripheral vasodilation as it could significantly depress 
all excitable membranes including the heart. (66). It may also act through inhibition of 
cough or strain associated with tracheal extubation that could cause hypertension and 
tachycardia. (67). Attenuation of the activity in afferent C fibers from the larynx may 
contribute toward this beneficial effect. (68). In addition, lidocaine may act centrally 
to increase the depth of anaesthesia. (69).  
Sharma VB, Prabhakar H et al (65) studied Dexmedetomidine and Lidocaine in 
preventing airway and haemodynamic responses during extubation in patients 
undergoing elective spine surgeries. This study included 60 patients, randomised in to 
three arms, with 20 patients in each arm. One arm received Dexmedetomidine 0.5 
mcg/kg, the second arm received Lidocaine 1.5 mg/kg, and the third arm received 
normal saline (placebo). Cough was graded from grade 1 to grade 5, with grade 1 
being no cough, grade 2 minimal cough (one or two attempts at coughing), grade 3 
moderate cough (three or four attempts at coughing), grade 4 heavy coughing (5 or 
more attempts at coughing) and grade 5 severe cough (laryngospasm, no breathing). 
16/20 (80%) had no cough in the Dexmedetomidine arm, whereas the rest 4/20 (20%) 
had grade 2 cough (mild cough). 13/20 (65%) patients had no cough in the Lidocaine 
arm, whereas, 7/20 (35%) had grade 2 cough (mild cough). 7/20 (35%) patients had 
no cough in the placebo group, whereas, 11/20 (55%) had grade 2 cough (mild 
cough), and 2/20 (10%) had grade 3 cough (moderate cough). The heart rate increased 
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in all the groups but the increase was more in patients in Lidocaine group than in 
Dexmedetomidine group. Only one patient had bradycardia in the Dexmedetomidine 
group. The MAP increased for the initial 3 minutes of drug administration in 
Dexmedetomidine group. However, Dexmedetomidine attenuated the increase in 
blood pressure to a greater degree than Lidocaine. The airway response was better 
attenuated with Dexmedetomidine than with Lidocaine. The need for postoperative 
analgesia was delayed after administration of Dexmedetomidine. It concluded that 
both Lidocaine and Dexmedetomidine were comparable in attenuating haemodynamic 
response, Dexmedetomidine was better in attenuating airway response, and there was 
no difference in time taken for emergence.   
Coughing may potentially trigger post thyroidectomy bleeding by causing 
slipping of ligatures and disruption in the haemostasis. It can significantly increase the 
mortality and morbidity.  Hence it is reasonable to take measures to prevent coughing 
during emergence from general anaesthesia after thryroidectomy. Both 
Dexmedtomidine and Lidocaine have been shown to decrease the occurrence of cough 
during tracheal extubation in various studies, but there is no study comparing these 
drugs in preventing cough during emergence from general anaesthesia after 
thyroidectomy. Also it is not a standard of care to administer either of these drugs 
during emergence from general anaesthesia after thyroidectomy. Hence, the purpose 
of this study is to determine whether the administration of Dexmedetomide or 
Lidocaine will minimise or prevent coughing during extubation in thyroidectomy, and 
to compare their effects.  
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NULL HYPOSTHESIS:  
 There is no difference between the effect of Dexmedetomidine and Lidocaine 
in preventing or minimising cough during emergence from general anaesthesia after 
thyroidectomy.  
STUDY DESIGN:  
This is a double-blinded randomised control trial, with Dexmedetomidine in 
one arm and Lidocaine in the other arm.  
 
METHODS:  
 The study proposal was submitted the Institutional Review Board (IRB), also 
including the Ethics Committee. After approval from the IRB, the study was 
registered in Clinical Trials Registry of India. Recruitment and data collection was 
started on 29th March 2017, and ended on 10th August 2017.  
Inclusion Criteria: 
1. All Adult Patients (Age ≥ 18)  
2. ASA I, II, III 
3. Patients undergoing Thyroidectomy 
4. Patients given Consent 
Exclusion Criteria:  
1. Known Hypersensitivity to Dexmedetomidine or Lidocaine 
2. Baseline Heart Rate < 60/minute 
3. Uncontrolled Systemic Hypertension 
4. URTI / LRTI within 2 weeks 
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5. Patients on Anti-arrhythmic Drugs 
6. Patients on Beta Blocker Drugs 
Intervention and Comparator Agents: 
Intervention Agent 1 – Dexmedetomidine (Intervention Agent) 
Intervention Agent 2 – Lidocaine (Comparator Agent) 
To compare intervention agents 1 and 2.  
Method of Randomisation: 
The patients were randomised in to one of two groups by computer generated 
block randomisation in blocks of 4.  
Method of Allocation Concealment: 
Sequentially numbered, sealed, opaque envelopes were used, and they were 
opened only in the operation theatre after the patient is 
anaesthetised.  
Blinding and Masking:  
It is a double blinded study as the participant and outcome assessors were 
blinded to treatment allocation. Masking was employed to prevent observer bias. An 
anaesthesiology technologist, not involved in the study, opened the envelope and 
loaded the drugs accordingly, and labelled with only study numbers on the syringes. 
The treating anaesthesiologist administered the drugs and observed the effect, and 
he/she was also blinded. As the methods of administration of the two drugs are 
different, all patients received two injections – one as an infusion over 15 minutes and 
the other as a bolus. One of them was the study drug and the other was normal saline. 
This is to blind the treating anaesthesiologist, who is also the observer of the effect.  
36 
 
 
Primary Outcome: 
The primary outcome is occurrence of no cough during emergence and in post 
anaesthesia care unit (PACU).  
Secondary Outcomes: 
The secondary outcomes are 
1. Haemodynamic response (Heart Rate, Blood Pressure) during emergence 
and in PACU. 
2. Time taken for awakening. 
Methodology:  
All adult patients over the age of 18, posted for thyroidectomy surgery by the 
department of Endocrine Surgery, Christian Medical College, Vellore were 
interviewed. Consent was taken by the primary investigator after explaining the 
procedure in detail in the ward in the evening prior to the operation. Consented 
patients were randomized in to two arms, the Dexmedetomidine arm and the 
Lidocaine arm. The patients underwent the surgery as per routine. All anaesthetic 
agents and techniques were standardised to eliminate confounding factors. Opaque, 
sealed envelope were opened outside the operating room, and the drugs were loaded 
appropriately and labelled with study number by an anaesthesiology technologist not 
involved in the study or the operation. Thus the treating anaesthesiologist is blinded. 
Group A received 1 mcg/kg of Dexmedetomidine (infused intravenously over 15 
minutes) and normal saline bolus. Group B received 2 mg/kg of Lidocaine (given as 
intravenous bolus) and normal saline infusion for 15 minutes. Heart rate and blood 
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pressure were recorded prior to induction, every 5 minutes intra-operatively. Any 
occurrence of cough during emergence, extubation, in PACU were recorded. Cough 
was graded as, grade 1 – no cough, grade 2 – mild cough – predominantly breathing, 
intermittent coughing (1-3 attempts at coughing), grade 3 – moderate cough - 
intermittent breathing, predominantly coughing (4 or more attempts at coughing), 
grade 4 - severe cough (laryngospasm, no breathing). Standard protocol was followed 
for all patients so as to eliminate confounding factors. The standardised protocol used 
is as follows: 
-No sedative premedication on the day prior to surgery or on the day of surgery 
- Standard monitors for intraoperative monitoring as per ASA guidelines 
- Induction of anaesthesia with Fentanyl 2 mcg/kg, Propofol 2mg/kg, Atracurium 0.5   
mg/kg 
- No Lidocaine at intubation 
- Size 6.5 ETT for female and size 7.0 ETT for male 
- ETT cuff pressure measured after intubation, kept between 20 to 30 cm of water 
- Dexamethasone 0.1 mg/kg IV after intubation 
- Isoflurane for maintenance of anaesthesia – MAC maintained between 0.8 to 1.0 
- Analgesia with Paracetamol 15 mg/kg (up to 1 g), Fentanyl up to 5 mcg/kg 
- No Morphine / Tramadol / Diclofenac / Regional Analgesia was administered 
- Intermittent Atracurium for muscle relaxation as required 
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- Study drug infusion started when closure of muscle layer started 
- The infusion rate set as body weight in ml/hour and stopped in 15 minutes 
- Isoflurane stopped when closure of skin started 
- Fresh gas flow increased and Reversal of muscle relaxant administered when the 
skin closure ended 
- Study drug bolus given as body weight/10 ml when MAC reached 0.3 
- ETT cuff pressure measured at MAC 0.3, kept between 20 to 30 cm of water 
- No calling or touching or stimulating the patient in any way 
-  Patients waited upon to breathe, open eyes / make purposeful movement 
- Shoulder roll / head ring not removed until shifting the patient to trolley 
- Oral suction given only after the patient awakened and then ETT removed 
- Occurrence of cough at extubation, 1 minute from extubation, 3 minutes from 
extubation, 5 minutes from extubation, 10 minutes from extubation, 15 minutes from 
extubation, 30 minutes from extubation and in PACU recorded 
- Haemodynamic responses (heart rate and blood pressure) also recorded at the same 
time points 
- Time taken to awaken calculated from the time of stoppage of isoflurane to the time 
of extubation 
- Data recorded in proforma with all timings 
- Grade 3 or grade 4 cough - treated with Propofol 
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Diagrammatic Algorithm of the Study: 
 
                        
 
 
 
 
  
 
 
 
 
 
 
 
              All Adult Patients for Thyroidectomy 
    Informed Consent obtained by Primary Investigator 
                               Randomisation 
                           Standard Anaesthesia 
Cough, HR, BP observed during and after Extubation, and recorded 
Exclude –  
Does not fulfil inclusion criteria 
No consent 
 
Include - ASA I, II, III 
Consent given 
Fulfilling inclusion criteria 
Group A                                                                Group B 
-Dexmedetomidine                                              -Lidocaine 
-1 mcg/kg infusion over 15 minutes                   -2 mg/kg of 2% solution bolus 
- Normal Saline bolus                                         - Normal Saline Infusion over 15 minutes 
 
Exclude Protocol Breach 
    Data Analysed 
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STATSITICAL ANALYSIS: 
 For the sample size calculation, the statistical input proportion of patients with 
no cough was taken from the reference article “Comparison of Dexmedetomidine, 
Lidocaine, and their combination in attenuation of Cardiovascular and Catecholamine 
responses to Tracheal Extubation and Anaesthesia emergence in Hypertensive 
Patients” by Ashraf M.A. Moustafa, Hatem Atalla, Hala M. Koptan, Department of 
Anaesthesia and Intensive Care, Menoufiya University, Egypt, as group I 
(Dexmedetomidine) & group II (Lidocaine) as 0.10 and 0.35 respectively. The sample 
size is calculated using Master software version 2.0.  
Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation: 
Proportion in Group I    0.1 
Proportion in Group II    0.35 
Estimated Risk Difference    0.25 
Power (1- beta) %     80 
Alpha Error (%)    5 
1 or 2 sided      2 
Required Sample Size for each Arm  43 
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With 80% power, 95% confidence interval and two-sided test, the study 
required totally 86 patients, 43 patients in each arm. To get more number for the equal 
allocation, totally 100 patients (Group I = 50: Group II = 50) were planned to be taken 
for the study to compare the effect of Dexmedetomidine and Lidocaine in preventing 
cough during emergence from general anaesthesia in patients undergoing 
thyroidectomy.  
A total of 105 patients were interviewed, and after obtaining informed consent, 
92 patients were included in the study, as the rest 13 patients did not give consent. 
Patients were randomised as mentioned before and data were collected. Apart from 
including the variables for primary and secondary objectives, the data included 
demographic details, comorbid conditions, anthropometry, allergy, smoking, airway 
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compression by the thyroid swelling, diagnosis and details of the operation done. Out 
of the 92 patients, there was protocol breach in 4 patents, hence they were excluded 
from analysis. Data were entered in Epidata software and analysed using SPSS 
software. 
 For continuous data, such as age, the descriptive statistics n, Mean, SD, 
Median, IQR, Minimum and Maximum were calculated. For categorical data, the number of 
patients, percentage and proportions were presented. Based on the normality of data, the 
parametric t test or non-parametric Mann-Whitny test were applied to the data, wherever 
required. Association between the intervention and outcome was analysed using Chi-Square 
test. Severity grade of cough were presented as number and percentage and compared. P-
values were reported as specified by the statistical software used, at least up to four decimal 
places. P-values less than 0.0001 were reported as provided by statistical software (e.g. 
'<0.0001'). All tests were two-sided at α=0.05 level of significance. Difference between two 
means was assessed using paired t test. Other statistical test was carried out as deemed. All 
statistical analysis was done using SPSS software version 17.0.  
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RESULTS:  
 88 patients in total were analysed, of which 44 belonged to group A 
(Dexmedetomidine) and 44 belonged to group B (Lidocaine).  
Group Distribution:  
 There were equal number of patients (44 in each) in both groups, hence the 
number and the percentages during analysis corresponded.  
 
 
 
 
 
 
Age Distribution:  
 38 (43.4%) patients belonged to the age group of 18 to 35 years, 48 (54.2%) 
patients belonged to the age group of 36 to 60 years, and only 2 (2.3%) patients were 
above 60 years old. In Dexmedetomidine group, 20 patients belonged to age less than 
35 years, 22 patients were between 36 and 60 years and 2 patients were above 60 
4444
Group Distribution
A - Dexmedetomidine B - Lidocaine
n = 88
Group A - Dexmedetomidine B – Lidocaine 
Number of Patients 44 44 
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years. In Lidocaine group 18 patients were less than 35 years, 26 patients were 
between 36 and 60 years, and no patient was above 60 years.  
Age A - Dexmedetomidine B – Lidocaine 
18 – 35 years 20 18 
36– 60 years 22 26 
>60 years 2 0 
 
 
Gender Distribution:  
28 out of 88 patients were males (31.8%), whereas 60 (68.2%) were females. In 
Dexmedetomidine group, 15 patients were males and 29 were females. In Lidocaine 
group, 13 patients were males and 31 were females.  
 
Gender A - Dexmedetomidine B - Lidocaine 
Male 15 13 
Female 29 31 
 
38
48
2
Age
18 - 35 36 - 60 >60 n = 88
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Body Mass Index:  
  43 patients (48.9%) in total were with normal BMI, 33 patients (37.5%) 
were overweight, 11 patients (12.5%) were obese, and 1 patient (1.1%) was morbidly 
obese. In Dexmedetomidne group, 22 patients were with normal BMI, 17 patients 
were overweight, 5 patients were obese. In Lidocaine group, 21 patients with normal 
BMI, 16 patients were overweight, 6 patients were obese, and 1 patient was morbidly 
obese.  
 
BMI (kg/m2) A - Dexmedetomidine B – Lidocaine 
<25 22 21 
25.01 – 30 17 16 
30.01 - 35 5 6 
>35 0 1 
 
28
60
Gender
Male Female n = 88
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Comorbidities:  
 9 patients had diabetes mellitus (5 in Dexmedetomidine group and 4 in 
Lidocaine group), 12 patients had hypertension (3 in Dexmedtomidine group and 9 in 
Lidocaine group), 2 patients had CKD (1 in each group), 1 patient had 
hyperthyroidism (belonged to Lidocaine group), 14 patients had hypothyroidism (8 in 
Dexmedetomidine group and 6 in Lidocaine group). 2 patients had bronchial asthma 
belonging to one group each. The patient in Lidocaine group had grade 2 cough at 
extubation, and the patient in Dexmedetomidien group had no cough at extubation. 
One patient had COPD, who was in Lidocaine group, had grade 2 cough at extubation.  
Comorbidities A - Dexmedetomidine B – Lidocaine 
Diabetes 5 4 
Hypertension 3 9 
CKD 1 1 
Hypothyroidism 8 6 
Hyperthyroidism 0 1 
Others 1 2 
22
17
5
0
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16
6
1
0
5
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Normal BMI Overweight Obese Morbidly Obese
Body Mass Index
A - Dexmedetomidine B - Lidocaine
n = 88
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ASA Status:  
 Out of 88 patients, 53 patients (27 patients in Dexmedetomidine group, 26 
patients in Lidocaine group) were ASA category I and 35 patients (17 patients in 
Dexmedetomidine group, 18 patients in Lidocaine group) were ASA category II. No 
patient was ASA category III.  
ASA Status A – Dexmedetomidine B – Lidocaine 
ASA I 27 26 
     ASA II 17 18 
         ASA III 0 0 
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8
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Allergy:  
 3 out of 88 patients had allergy / atopy, out of which 2 had cough at extubation 
(1 in each group).  
 
Allergy A - Dexmedetomidine B – Lidocaine 
Yes 2 1 
        No 42 43 
 
Allergy n = 3 
 
 
 
 
 
 
1 1
0
1
0
1
2
No Cough Cough
Allergy
A - Dexmedetomidine B - Lidocaine
n = 88
                Cough A - Dexmedetomidine B - Lidocaine 
                  Yes 1 1 
       No 1 0 
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Smoking:  
 10 out of 88 patients (11.4%) gave histroy of smoking. Out of those 10, 5 had 
no cough at extubation (3 in Dexmedetomidine group and 2 in Lidocaine group), and 
5 had cough at extubation (all 5 in Lidocaine group).  
Smoking A - Dexmedetomidine B – Lidocaine 
Yes 3 7 
        No 41 37 
 
    Smoking n = 10 
 
 
 
 
 
 
3
0
2
5
0
1
2
3
4
5
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No Cough Cough
Smoking
A - Dexmedetomidine B - Lidocaine
n = 88
Cough A - Dexmedetomidine B – Lidocaine 
Yes 0 5 
        No 3 2 
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Tracheal Compression:  
 34 patients had compression of the trachea by the thyroid swelling, diagnosed 
either clinically or by imaging.  
Tracheal Compression A - Dexmedetomidine B – Lidocaine 
Yes 18 16 
        No 26 28 
 
In the 34 patients with tracheal compression, cough was seen in 19 (55.9%) 
patients (7 patients in Dexmedetomidine group and 12 in Lidocaine group) and 15 (11 
in Dexmedetomidine group and 4 in Lidocaine group) patients (44.1%) had no cough 
at extubation. 
Tracheal Compression n = 34 
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No Cough Cough
Tracheal Compression
A - Dexmedetomidine B - Lidocaine
n = 88
                Cough A - Dexmedetomidine B – Lidocaine 
                  Yes 7 12 
       No 11 4 
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Indication for Surgery:  
 Majority of patients were operated for multinodular goitre and papillary 
carcinoma, and the distribution between the study arms were fairly equal.  
 
Indication for Surgery A - Dexmedetomidine B – Lidocaine 
MNG 19 22 
Papillary Ca 20 19 
Others 5 3 
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Type of Operation:  
 71 out of 88 patients had total thyroidectomy (TT) done, 5 patients had 
hemithyroidectomy (HT), with equal distribution between the two groups. Those 
patients had both thyroidectomy and neck dissections (12 patients), were more in the 
Dexmedetomidine group than in Lidocaine group.   
 
Type of Surgery A - Dexmedetomidine B – Lidocaine 
TT 34 37 
HT 2 3 
TT + ND 8 4 
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Duration of Surgery:  
 The average duration of surgery was 145.95 minutes. 13 patients had duration 
of surgery less than 100 minutes (8 in Dexmedetomidine group and 5 in Lidocaine 
group), 65 patients had duration of surgery between 100 and 200 minutes (29 in 
Dexmedetomidine group and 36 in Lidocaine group), 10 patients had duration of 
surgery more than 200 minutes (7 in Dexmedtomidine group and 3 in Lidocaine 
group).  
Duration of Surgery A - Dexmedetomidine B – Lidocaine 
<100 minutes 8 5 
100 – 200 minutes 29 36 
>200 minutes 7 3 
 
 
Out of 13 patients with duration of surgery less than 100 minutes, 6 had cough 
at extubation (all 6 in Dexmedetomidine group) and 7 had no cough at extubation (2 
in Dexmedetomidine group and 5 in Lidocaine group). Out of 65 patients with 
duration of surgery 100 to 200 minutes, 30 had cough (15 in each group), and 35 had 
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no cough (14 in Dexmedetomidine group and 21 in Lidoacaine group). Out of 10 
patients with duration of surgery more than 200 minutes, 4 had cough (3 in 
Dexmedetomidine group and 1 in Lidocaine group), and 6 had no cough (4 in 
Dexmedetomidine group and 2 in Lidocaine group).  
Duration of Surgery A - Dexmedetomidine B – Lidocaine 
Yes Cough No Cough Yes Cough No Cough 
<100 minutes 6 2 0 5 
100 – 200 minutes 15 14 15 21 
>200 minutes 3 4 1 2 
 
 
Mode of Intubation:  
 86/88 patients were intubated with direct laryngoscopy using Mcintosh blade. 
Only 2 patients were intubated with video laryngoscope (Glidescope), (both 
Dexmedetomidine group).  
Mode of Intubation A – Dexmedetomidine B - Lidocaine 
Direct Laryngoscope 42 44 
     Video Laryngoscope 2 0 
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Number of Attempts at Intubation:  
 Out of 88 patients 85 were intubated in one attempt, and 3 patients were 
intubated in two attempts (1 in Dexmedetomidine group and 2 in Lidocaine group).  
No. of Intubation Attempts A – Dexmedetomidine B - Lidocaine 
1 43 42 
2 1 2 
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Use of Stylet:  
 Out of 88 patients, stylet was used in 79 patients (39 patients in 
Dexmedetomidine group, 40 patients in Lidocaine group). Out of the 79, 44 patients 
had cough at extubation (21 patients in Dexmedtomidine group and 23 patients in 
Lidocaine group). Bougie was used for intubation in only one patient out of 88 
patients.  
Stylet Used A – Dexmedetomidine B – Lidocaine 
Yes 39 40 
No 5 4 
 
 
Usage of Propofol towards Extubation: 
Propofol was used as a rescue drug to prevent worsening of cough towards 
extubation in 7 patients (all belonging to Lidocaine group). In 4 patients propofol was 
used as they moved during closure of skin. 2 patients had grade 2 cough during 
closure and hence propofol was used. One patient had grade 3 cough 1 minute after 
extubation for which 30 mg of propofol was given. Out of these 6 patients in whom 
propofol was used prior to extubation, 4 patients had grade 1 cough at extubation, 2 
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patients had grade 2 cough at extubation, and 1 patient had grade 3 cough at 
extubation and at 1 minute from extubation. Out of these 7 patients in whom propofol 
was used towards extubation, time taken to awaken was 17, 18, 20 minutes in 3 
patients, 22 minutes in 2 patients, 26 minutes in 2 patients. No patient in 
Dexmedetomidine group received propofol towards extubation.  
 
Propofol Used A – Dexmedetomidine B - Lidocaine P value 
Yes 0 7 0.006 
No 44 37 0.006 
 
  
 
 
 
 
 
 
 
Cough in PACU:  
Only 1 out of 88 patients had cough in post anaesthesia care unit (PACU). It 
was one episode of grade 3 cough. This patient belonged to Dexmedtomindine group. 
This patient had cough at 10 minutes from extubation. There was no external stimulus 
at that point of time. This patient had no cough at extubation or prior to extubation.  
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Temperature at Extubation:  
All 88 patients had recorded oral temperature of 35.0°C or more. No patient 
had hypothermia at any point during the surgery and extubation.  
Occurrence of Neck Haematoma / Bleeding:  
There was no occurrence of neck haematoma or bleeding in any of the 88 
patients in the post-operative period until discharge. However, 1 patient had increased 
drain output for which the patient was hospitalised for more than 3 days post-
operatively.  
Duration of Hospital Stay:  
 11/88 (12.5%) patients (6 in Dexmedtomidine group, 5 in Lidocaine group) 
were admitted for more than 3 days post-operatively. The reasons were hypocalcaemia 
(8), chyle leak (1), worsened hoarseness (1) and increased drain output (1).  
Duration of Hospital Stay A – Dexmedetomidine B - Lidocaine p value 
≤ 3 Days 38 39 0.747 
>3 Days 6 5 0.747 
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Cough at Extubation:  
 21 out of 44 patients (47.7%) in Dexmedetomidine group had no cough 
compared to 22 out of 44 patients (50%) in Lidocaine group who had no cough at 
extubation. 18 out of 44 patients (40.9%) in Dexmedtomidine group had grade 2 
cough compared to 16 out of 44 patients (36.4%) in Lidocaine group who had grade 2 
cough. 5 patients (11.4%) in Dexmedtomidine group had grade 3 cough, and 6 
patients (13.6%) in Lidocaine group had grade 3 cough. No patient had grade 4 cough 
in either of the groups at extubation.  
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Cough at Extubation A - Dexmedetomidine B – Lidocaine p value 
Grade 1 (No Cough) 21 22 0.831 
Grade 2 (Mild Cough) 18 16 0.661 
Grade 3 (Moderate Cough) 5 6 0.747 
Grade 4 (Severe Cough) 0 0 1.000 
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 39/44 (88.6%) patients in Dexmedtomidine group had mild or no cough 
compared to 38/44 (86.4) patients in Lidocaine group had mild or no cough. 
Significant cough (grade 3 cough) occurred in 5/44 (11.4%) patients in 
Dexmedtomidine group compared to 6/44 (13.6%) patients in Lidocaine group.  
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Cough at Extubation A - Dexmedetomidine B – Lidocaine p value 
Mild or No Cough 39 38 0.747 
Moderate Cough 5 6 0.747 
Severe Cough 0 0 1.000 
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Cough at 1 Minute from Extubation:  
 42 out of 44 patients (95.5%) in Dexmedtomidine group had no cough 
compared to 37 out of 44 patients (84.1%) in Lidocaine group who had no cough at 1 
minute from extubation. 2 out of 44 patients (4.5%) had grade 2 cough in 
Dexmedtomidine group compared to 3 out of 44 patients (6.8%) in Lidocaine group 
who had grade 2 cough. No patient in Dexmedtomidine group had grade 3 cough, and 
4 patients (9.1%) in Lidocaine group had grade 3 cough. No patient had grade 4 cough 
in either of the groups at 1 minute from extubation.  
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Grade 2 (Mild Cough) 2 3 0.645 
Grade 3 (Moderate Cough) 0 4 0.041 
Grade 4 (Severe Cough) 0 0 1.000 
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Cough at 3 Minutes from Extubation:  
 42 out of 44 patients (95.5%) in Dexmedtomidine group had no cough 
compared to all 44 patients (100%) in Lidocaine group who had no cough at 3 minute 
from extubation. 2 out of 44 patients (4.5%) had grade 2 cough in Dexmedtomidine 
group compared to no patient in Lidocaine group who had grade 2 cough. No patient 
had grade 3 or grade 4 cough in either of the groups at 3 minute from extubation.  
 
 
 
 
42
2 0 0
44
0 0 0
0
5
10
15
20
25
30
35
40
45
50
Grade 1 Grade 2 Grade 3 Grade 4
Cough at 3 Minutes from Extubation
A - Dexmedetomidine B - Lidocaine n = 88
Cough at 3 minutes A - Dexmedetomidine B – Lidocaine p value 
Grade 1 (No Cough) 42 44 0.153 
Grade 2 (Mild Cough) 2 0 0.153 
Grade 3 (Moderate Cough) 0 0 1.000 
Grade 4 (Severe Cough) 0 0 1.000 
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Cough at 5 Minutes from Extubation:  
 All 44 patients (100%) in Dexmedtomidine group had no cough compared to 
43 out of 44 patients (97.7%) in Lidocaine group who had no cough at 5 minutes from 
extubation. No patient had grade 2 cough in Dexmedtomidine group compared to 1 
out of 44 patients (2.3%) in Lidocaine group who had grade 2 cough. No patient had 
grade 3 or grade 4 cough in either of the groups at 5 minutes from extubation.  
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Cough at 5 minutes A - Dexmedetomidine B – Lidocaine p value 
Grade 1 (No Cough) 44 43 0.314 
Grade 2 (Mild Cough) 0 1 0.314 
Grade 3 (Moderate Cough) 0 0 1.000 
Grade 4 (Severe Cough) 0 0 1.000 
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Cough at 10 Minutes from Extubation:  
 43 out of 44 patients (97.7%) in Dexmedtomidine group had no cough 
compared to all 44 patients (100%) in Lidocaine group who had no cough at 10 
minutes from extubation. No patient had grade 2 cough in either of the groups. 1 
patient (2.3%) had grade 3 cough in Dexmedtomidine group, and no patient had grade 
3 cough in Lidocaine group. No patient had grade 4 cough in either of the groups at 10 
minutes from extubation.  
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Grade 2 (Mild Cough) 0 0 1.000 
Grade 3 (Moderate Cough) 1 0 0.314 
Grade 4 (Severe Cough) 0 0 1.000 
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Cough at 15 Minutes from Extubation:  
 No patient had any cough in either of the groups at 15 minutes from extubation.  
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Cough at 15 minutes A - Dexmedetomidine B – Lidocaine p value 
Grade 1 (No Cough) 44 44 1.000 
Grade 2 (Mild Cough) 0 0 1.000 
Grade 3 (Moderate Cough) 0 0 1.000 
Grade 4 (Severe Cough) 0 0 1.000 
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Cough at 30 Minutes from Extubation:  
 No patient had any cough in either of the groups at 30 minutes from extubation.  
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Cough at 30 minutes A - Dexmedetomidine B – Lidocaine p value 
Grade 1 (No Cough) 44 44 1.000 
Grade 2 (Mild Cough) 0 0 1.000 
Grade 3 (Moderate Cough) 0 0 1.000 
Grade 4 (Severe Cough) 0 0 1.000 
67 
 
Mean Heart Rate from Pre-Induction to Start of Infusion:  
 The mean heart rate per minute (HR) at pre-induction in Dexmedtomidine 
group was 88.82, and in Lidocaine group was 86.70. At intubation it was 95.84 in 
Dexmedtomidine group and 91.75 in Lidocaine group. At the time of start of the 
infusion the mean heart rate in Dexmedtomidine group was 81.93, and in Lidocaine 
group was 81.98. 
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Mean Heart Rate from Stoppage of Isoflurane to Administration of Bolus:  
 The mean heart rate per minute (HR) at stoppage of isoflurane in 
Dexmedetomidine group was 72.41, and in Lidocaine group was 82.75. At 
administration of reversal of muscle relaxant, it was 88.95 in Dexmedetomidine group 
and 89.30 in Lidocaine group. At the time of administration of bolus, the mean heart 
rate in Dexmedtomidine group was 69.93, and in Lidocaine group was 90.98.  
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Mean Heart Rate from Extubation to 30 minutes from Extubation:  
 The mean heart rate per minute (HR) at extubation in Dexmedetomidine group 
was 96.91, and in Lidocaine group was 98.07. At 1 minute from extubation it was 
78.91 in Dexmedetomidine group and 99.32 in Lidocaine group. At 3 minutes from 
extubation it was 78.23 in Dexmedetomidine group and 97.82 in Lidocaine group. At 
5 minutes from extubation it was 75.36 in Dexmedetomidine group and 91.43 in 
Lidocaine group. At 10 minutes from extubation it was 73.98 in Dexmedetomidine 
group A and 90.00 in Lidocaine group. At 15 minutes from extubation it was 73.86 in 
Dexmedetomidine group and 85.89 in Lidocaine group. At 30 minute from extubation 
it was 74.36 in Dexmedetomidine group and 103.39 in Lidocaine group.  
 
 
 
Mean Heart Rate A - Dexmedetomidine B – Lidocaine p value 
Extubation 96.91 98.07 0.953 
1 Minute from Extubation 78.91 99.32 0.000 
3 Minute from Extubation 78.23 97.82 0.000 
5 Minute from Extubation 75.36 91.43 0.000 
10 Minute from Extubation 73.98 90.00 0.000 
15 Minute from Extubation 73.86 85.89 0.000 
30 Minute from Extubation 74.36 103.39 0.097 
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Average Mean Arterial Pressure from Pre-Induction to Start of Infusion:  
 The average mean arterial pressure in mm Hg (MAP) at pre-induction in 
Dexmedetomidine group was 94.14, and in Lidocaine group was 95.86. At intubation 
it was 92.00 in Dexmedetomidine group and 110.41 in Lidocaine group. At the time 
of start of the infusion the average MAP in Dexmedetomidine group was 76.41, and in 
Lidocaine group was 76.93.  
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Average MAP from Stoppage of Isoflurane to Administration of Bolus:  
 The average MAP in mm Hg at stoppage of isoflurane in Dexmedetomidine 
group was 74.80, and in Lidocaine group was 77.20. At administration of reversal of 
muscle relaxant, it was 79.57 in Dexmedetomidine group and 121.00 in Lidocaine 
group. At the time of administration of bolus, the average MAP in Dexmedetomidine 
group was 84.18, and in Lidocaine group was 88.11.  
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Stoppage of Isoflurane 74.80 77.20 0.284 
Reversal of Muscle Relaxant 79.57 121.00 0.089 
Bolus Admisitration 84.18 88.11 0.121 
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Average MAP from Extubation to 30 minutes from Extubation:  
 The average MAP in mm Hg at extubation in Dexmedetomidine group was 
81.59, and in Lidocaine group was 93.61. At 1 minute from extubation it was 83.86 in 
Dexmedetomidine group and 95.89 in Lidocaine group. At 3 minutes from extubation 
it was 82.77 in Dexmedetomidine group and 93.77 in Lidocaine group. At 5 minutes 
from extubation it was 79.77 in Dexmedetomidine group and 88.23 in Lidocaine 
group. At 10 minutes from extubation it was 78.09 in Dexmedetomidine group and 
86.66 in Lidocaine group. At 15 minutes from extubation it was 77.84 in 
Dexmedetomidine group and 119.82 in Lidocaine group. At 30 minute from 
extubation it was 93.39 in Dexmedetomidine group and 87.00 in Lidocaine group.  
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Extubation 81.59 93.61 0.000 
1 Minute from Extubation 83.86 95.89 0.000 
3 Minute from Extubation 82.77 93.77 0.000 
5 Minute from Extubation 79.77 88.23 0.001 
10 Minute from Extubation 78.09 86.66 0.001 
15 Minute from Extubation 77.84 119.82 0.079 
30 Minute from Extubation 93.39 87.00 0.656 
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Mean Systolic Pressure from Pre-Induction to Start of Infusion:  
 The mean systolic blood pressure in mm Hg (SBP) at pre-induction in 
Dexmedetomidine group was 131.68, and in Lidocaine group was 132.41. At 
intubation it was 121.70 in Dexmedetomidine group and 125.45 in Lidocaine group. 
At the time of start of the infusion the mean SBP in Dexmedetomidine group was 
104.34, and in Lidocaine group was 102.16.  
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Mean SBP from Stoppage of Isoflurane to Administration of Bolus:  
 The mean SBP in mm Hg at stoppage of isoflurane in Dexmedetomidine group 
was 100.25, and in Lidocaine group was 102.30. At administration of reversal of 
muscle relaxant, it was 104.86 in Dexmedetomidine group and 115.52 in Lidocaine 
group. At the time of administration of bolus, the mean SBP in Dexmedetomidine 
group was 113.32, and in Lidocaine group was 117.02. 
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Mean SBP from Extubation to 30 minutes from Extubation:  
 The mean SBP in mm Hg at extubation in Dexmedetomidine group was 
128.25, and in Lidocaine group was 123.82. At 1 minute from extubation it was 
115.95 in Dexmedetomidine group and 130.32 in Lidocaine group. At 3 minutes from 
extubation it was 113.82 in Dexmedetomidine group and 126.82 in Lidocaine group. 
At 5 minutes from extubation it was 132.64 in Dexmedetomidine group and 125.50 in 
Lidocaine group. At 10 minutes from extubation it was 112.32 in Dexmedetomidine 
group and 125.91 in Lidocaine group. At 15 minutes from extubation it was 111.20 in 
Dexmedetomidine group and 126.14 in Lidocaine group. At 30 minute from 
extubation it was 113.18 in Dexmedetomidine group and 125.02 in Lidocaine group. 
 
 
Mean SBP A - Dexmedetomidine B – Lidocaine p value 
Extubation 128.25 123.82 0.811 
1 Minute from Extubation 115.95 130.32 0.000 
3 Minute from Extubation 113.82 126.82 0.000 
5 Minute from Extubation 132.64 125.50 0.700 
10 Minute from Extubation 112.32 125.91 0.000 
15 Minute from Extubation 111.20 126.14 0.000 
30 Minute from Extubation 113.18 125.02 0.000 
77 
 
 
Time Taken to Awaken:  
 In Dexmedetomidine group, 2 patients took less than 10 minutes to awaken, 10 
patients took between 11 and 20 minutes to awaken, and 32 patients took more than 
20 minutes to awaken. In Lidocaine group, 1 patient took less than 10 minutes to 
awaken, 25 patients took between 11 and 20 minutes to awaken, and 18 patients took 
more than 20 minutes to awaken.  
 
Time Taken to Awaken A - Dexmedetomidine B - Lidocaine p value 
<10 minutes 2 1 0.557 
11 – 20 minutes 10 25 0.001 
>20 minutes 32 18 0.003 
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The average time taken to awaken in Dexmedetomidine group was 25.18 
minutes, and in Lidoacine group, it was 19.86 minutes.  
 A - Dexmedetomidine B - Lidocaine p value 
Average Time Taken to Awaken 25.18 19.86 0.000 
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DISCUSSION:  
 There was equal number of allocation in both the groups. The intended number 
for a power 80 was 43 in each arm, and there were 44 in each arm analysed. By 
randomisation, patients in both the groups were fairly matched with respect to age, 
gender, ASA status, comorbidities and body mass index. The indication for surgery, 
type of operation and the duration of operation did not vary much between the groups.  
There was no significant association between cough at extubation and allergy, 
smoking, tracheal compression, duration of surgery and usage of stylet for intubation.  
Propofol was used towards extubation in 7 patients (4 patients moved, 3 
patients had grade 2 cough), and all patients belonged to Lidocaine arm. Patients may 
have responded to stimulus due to skin suturing, or the endotracheal tube as isoflurane 
was stopped when closure started, and the MAC started decreasing. There was no 
such occurrence in Dexmedetomidne arm. This is a significant difference with respect 
to blunting response during emergence from general anaesthesia (p value = 0.025). 
This could probably be due to the observation that Dexmedetomidine attenuates 
hemodynamic responses to tracheal intubation, decreases plasma catecholamine 
concentrations during anaesthesia, decreases peri-operative requirements for inhaled 
anaesthetics and opioids. (58) (1)  
The incidence of cough during emergence from general anaesthesia in the 
presence of endotracheal tube has been observed as ranging between 38 and 96%. (17) 
(18). In our study, the overall incidence of cough at extubation is 51% (45/88 in both 
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groups combined). But the incidence of significant cough at extubation is only 12.5% 
(11/88).  
Qing Fan et al (43) studied Dexmedetomidine and Remifentanil in preventing 
cough during extubation in patients undergoing ear surgeries. Smooth extubation 
without cough was achieved in 88% (22/25 patients) with 0.7 mcg/kg 
Dexmedetomidine. In our study, extubation without significant cough was achieved in 
88.6% (39/44 patients) with 1 mcg/kg of Dexmedetomidine, which is similar to the 
observation by Qing Fan et al.  
Yukioka H et al (64) found the incidence of coughing to be 0% (0/20 patients) 
with 2.0 mg/kg Lidocaine in patients undergoing obstetric, urologic, gynaecologic and 
general surgeries. In our study, significant coughing with 2 mg/kg Lidocaine was 
observed in 13.6% (6/44 patients). The probable reason for the higher incidence of 
cough is the type of surgery, because in thyroid surgeries the dissection around the 
trachea can itself cause irritation and increase the likelihood of occurrence of cough.  
Ashraf MA Moustafa et al (53) compared the efficacy of the Dexmedetomidine 
and Lidocaine during extubation. Smooth extubation without cough or with minimal 
cough was achieved in 75% (15/20 patients) with 1 mg/kg Lidocaine, and 30% (6/20 
patients) with 0.1 mcg/kg Dexmedetomidine, (p value <0.05), stating that there is 
significant difference between the two.  
Sharma VB, Prabhakar H et al (65) compared Dexmedetomidine and Lidocaine 
in preventing airway responses during extubation in patients undergoing elective spine 
surgeries. They reported that there was no cough at extubation in 80% (16/20 patients) 
with Dexmedetomidine 0.5 mcg/kg, and in 65% (13/20 patients) with Lidocaine 1.5 
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mg/kg. Hence Dexmedetomidne and Lidocaine were comparable in preventing cough 
during extubation (p value = 0.288).  
In our study, extubation with no cough or mild cough was achieved in 88.6% 
(39/44 patients) with 1 mcg/kg Dexmedetomidine, and in 86.4% (38/44 patients) with 
2 mg/kg Lidocaine, with no significant difference (p value 0.891). The difference of 
observation between these studies is due to difference in the dose of the drugs used. 
Only 5/44 patients (11.4%) had grade 3 (moderate) cough in Dexmedetomidine 
group, and only 6/44 patients (13.6%) had grade 3 (moderate) cough in Lidocaine 
group. No patient had grade 4 (severe) cough in both groups. Hence, both 
Dexmedetomidine and Lidocaine are found to be effective and equal in preventing 
cough at extubation.  
 Post extubation, only 1/44 patients (2.3%) had grade 3 (moderate) cough in 
Dexmedetomidine group, whereas, 4/44 patients (9.1%) had grade 3 (moderate) cough 
in Lidocaine group. There is no significant difference between Dexmedetomidine and 
Lidocaine in preventing post extubation cough (p value = 0.167). No patient had grade 
4 (severe) cough on both the groups post extubation.  
Although the mechanism by which intravenous lidocaine suppresses respiratory 
and laryngeal reflex responses is largely unknown, possible effects may include 
general anaesthesia, depression of motor function and direct blockade of noxious 
stimuli (60). A reflex response to laryngeal stimulation is mediated at subcortical level 
and therefore, a cortical effect may not be adequate to reduce the response to laryngeal 
stimulation. (70). Respiratory and laryngeal reflex responses elicited 10 minutes after 
the intravenous administration of lidocaine were different from those elicited 
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2 minutes after administration, even though Bispectral index values were similar at 
these two time intervals. So a direct anaesthetic effect of lidocaine does not 
sufficiently explain the mechanism of suppression of response to laryngeal 
stimulation. (60) (70). Lidocaine may cause suppression of cough by causing 
depression of brain stem functions. Lidocaine may also act by anaesthetising cough 
receptors in the hypopharynx and trachea. (61). Administration of intravenous 
lidocaine may suppress chemically and mechanically induced airway reflexes, 
including cough reflex. (61).  
 Dexmedetomidine is well known to attenuate haemodynamic responses to 
tracheal intubation, and it is also used for sedation in post-operative critically ill 
patients with ETT in situ. It causes co-operative conscious sedation by stimulating the 
locus coeruleus in the brain stem, resulting in inhibition of the sympathetic vasomotor 
centre of the brain as compared to other sedatives which act upon GABA-ergic 
pathways causing decrease or loss of consciousness. (71). Dexmedetomidine 
decreases acetylcholine release during cholinergic electrical field stimulation in the 
airway and may provide a probable mechanism for the observed use of 
Dexmedetomidine in attenuating airway reactivity during manipulation. (71). 
Dexmedetomidine also decreases C-fibre mediated airway smooth muscle contraction, 
which may probably be an underlying mechanism for cough suppression by 
dexmedetomidine. (71).  
 Dexmedtomidine significantly produced a stable heart rate trend during 
emergence compared to Lidocaine. There was no significant difference in the heart 
rate between the two groups at the time of reversal of muscle relaxant, at the time of 
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extubation, and at 30 minutes from extubation. At the time of administration of 
reversal, the tachycardia caused by the glycopyrrolate could have narrowed the 
difference between the two groups.  
  
Ashraf MA Moustafa et al (53) compared haemodynamic responses between 
Dexmedetomidine and Lidocaine in hypertensive patients undergoing orthopaedic 
surgeries. They observed that HR and MAP increased temporarily after tracheal 
extubation in patients receiving Lidocaine. However, these hemodynamic changes 
were suppressed in those receiving Dexmedetomidine.  
We have observed that, compared to Lidocaine, Dexmedetomidine 
significantly produced a stable heart rate, mean arterial pressure and systolic blood 
pressure during emergence, which was similar to the observation by Ashraf MA 
Moustafa et al. (53) 
Sharma VB, Prabhakar H et al (65) studied Dexmedetomidine and Lidocaine in 
preventing airway and haemodynamic responses during extubation in patients 
undergoing elective spine surgeries. They observed that the time taken for emergence 
was 7.7 ± 3.8 minutes in Dexmedetomidine group, and in Lidocaine group it was 6.5 
± 1.9 minutes, hence no difference between the two (p value = 0.1).  
 In our study there was significant difference in time taken to awaken between 
the two groups. On an average, patients in Dexmedetomidine arm took 5.32 minutes 
more to awaken than did patients in Lidocaine arm. The difference in such observation 
from the above mentioned study is probably due to the difference in the dose of 
Dexmedetomidine used.  
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LIMITATIONS:  
 In our study, we did not include a placebo arm to compare both 
Dexmedetomidine and Lidocaine with placebo. We used historical cohort to assume 
the standard rate of emergence cough. This may not be situation in our institution as 
every place has a refined way of extubation and hence the incidence may be different. 
Different doses of dexmetomidine was not used to study the dose dependent effects.  
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CONCLUSION:  
 Both Dexmedetomidine at 1 mcg/kg and Lidocaine at 2 mg/kg are effective and 
equal in preventing cough during extubation.  
Dexmedetomidine significantly attenuates haemodynamic response during 
emergence compared to Lidocaine.  
Dexmetomidine helped to prevent early movement and cough towards the end 
of the surgery, but lidocaine did not always guarantee this. 
Dexmedetomidine caused significant delay in awakening compared to 
Lidocaine.  
Dexmedetomidine is a useful adjuvant to help in smooth extubation for head 
and neck surgery where one would want to minimise post-operative bleeding, though 
there is a slight delay in awakening. Future studies comparing different doses of 
Dexmedetomidine and Lidocaine with a placebo arm may be needed to ascertain and 
compare the effect of these drugs in preventing cough during emergence from general 
anaesthesia in surgeries where bleeding in the postoperative period is detrimental.  
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Consent to Take Part in a Clinical Trial 
Study Title:   
Comparison of Dexmedetomidine and Lidocaine in Preventing Cough During Emergence from 
General Anaesthesia for Thyroidectomy 
Study Number: 
Participant’s Name:  
Date of Birth / Age (in years): 
I, _____________________________________________________________ 
 
___________, Son / Daughter of  ___________________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provided to me regarding this study and have clarified 
any doubts that I had. [    ] 
I also understand that my participation in this study is entirely voluntary and that I am free to withdraw 
permission to continue to participate at any time without affecting my usual treatment or my legal 
rights [    ] 
I also understand that neither I, nor my doctors, will know which drug I will receive (Lidocaine or 
Dexmedetomidine) [    ]  
I understand that I will receive free treatment for any study related injury or adverse event but I will 
not receive and other financial compensation [    ] 
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. I agree to this access [    ]  
I understand that my identity will not be revealed in any information released to third parties or 
published [    ] 
I agree to pay for any investigation routinely warranted for my treatment [    ] 
I voluntarily agree to take part in this study [    ] 
Name:       Signature:  
                                                                                             Date:  
Name of witness:      Signature:  
Relation to participant:                                                   Date: 
Name of the Doctor:      Signature:  
                                                                                             Date:  
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Christian Medical College, Vellore 
Department of Anaesthesia 
Comparison of Dexmedetomidine and Lidocaine in Preventing Cough During Emergence from 
General Anaesthesia for Thyroidectomy: Double Blinded Randomized Controlled Study 
Information sheet 
You are invited to be part of a study to improve the current knowledge regarding the role of drugs to 
prevent cough while waking up general anaesthesia for thyroid removal operation. This study will 
help other patients who later come to hospital for the same operation.  By agreeing to be a part of 
this study, you will contribute to scientific knowledge.  
The information collected from you will include  
1. History – This includes details regarding your general health and the disease 
for which you are undergoing the operation. 
2. Clinical Examination – Besides the regular doctors rounds, the primary 
investigator and the treating anaesthesiologist will examine you. 
You will be examined post operatively by the treating anaesthesiologist in the ward and data will be 
collected and analysed.  
Whether you accept or decline to be a part of this study will not affect your further treatment in this 
hospital.  
Although you may not directly benefit by enrolling in this study, you will be contributing to scientific 
knowledge. 
You are scheduled to undergo total / hemi thyroidectomy under general anaesthesia. Considering the 
type of surgery and anaesthesia, you have a risk of suffering from cough at the end of surgery, which 
further can cause bleeding from operation site. The current recommendation of therapy does not 
involve administration of any drug to prevent cough.  The idea of this research is to study and compare 
the effects of two drugs, namely Lidocaine and Dexmedetomidine (both given as injection), to prevent 
cough. By being a part of the study you will be randomly allotted into two groups.  In one group, 
patients will receive Dexmedetomidine and the second group patients will receive Lidocaine.  Both of 
these regimens are well studied and are routinely used during operations to prevent stress response.  
The operative technique and all other anaesthetic approaches will be similar. The occurrence of cough 
will be observed and treated accordingly as usual.  
We wish to study this in detail and are therefore conducting a scientific study.   
All details including personal data, assessment of the doctor during and after the operation will be 
kept confidential. 
These drugs will be given free of cost to you. The rest of the treatment cost will be the same as 
discussed with your surgery unit doctors.  
Participation in this study is purely voluntary, and you can withdraw from the study at any time, and 
that refusal to participate will not involve any penalty or loss of benefits to which you are otherwise 
entitled.  
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PROTOCOL SHEET 
 
- No sedative premedication on the day prior to surgery or on  
  the day of surgery 
- Standard monitors for intraoperative monitoring as per  
  ASA guidelines 
- Induction of anaesthesia with Fentanyl 2 mcg/kg, Propofol 2  
  mg/kg, Atracurium 0.5 mg/kg 
- No Lidocaine at intubation 
- Size 6.5 ETT for female and size 7.0 ETT for male 
- ETT cuff pressure measured after intubation and the same  
  kept between 20 to 30 cm of water 
- Dexamethasone 0.1 mg/kg IV after intubation 
- Isoflurane for maintenance of anaesthesia – MAC  
  maintained between 0.8 to 1.0 
- Analgesia with Paracetamol 15 mg/kg (up to 1 g),  
  Fentanyl up to 5 mcg/kg 
- No Morphine / Tramadol / Diclofenac / Regional Analgesia 
- Intermittent Atracurium for muscle relaxation as required 
- Study drug infusion started when closure of muscle layer started 
- The infusion rate set as body weight in ml/hour and stopped in     
  15 minutes 
- Isoflurane stopped when closure of skin started 
- Fresh gas flow increased and Reversal of muscle relaxant  
  administered when the skin closure ended 
- Study drug bolus given as body weight/10 ml when MAC reached  
  0.3 
- ETT cuff pressure measured at MAC 0.3, and kept  
  between 20 to 30 cm of water 
- No calling or touching or stimulating the patient in any way 
-  Patients waited upon to breathe, open eyes / make purposeful  
   movement 
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- Shoulder roll / head ring not removed until shifting the patient to  
   trolley 
- Oral suction given only after the patient awakened and then ETT removed 
- Occurrence of cough at extubation, 1 minute from extubation, 3  
  minutes from extubation, 5 minutes from extubation, 10 minutes from   
  extubation, 15 minutes from extubation, 30 minutes from extubation  
  and in PACU recorded 
- Haemodynamic responses (heart rate and blood pressure) also  
  recorded at the same time points 
- Time taken to awaken calculated from the time of stoppage of  
  isoflurane to the time of extubation 
- Data recorded in proforma with all timings 
- Grade 3 or grade 4 cough - treated with Propofol and the same   
   recorded in the proforma 
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